KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Profit After Tax (2016 - 2025)

CRISPR Therapeutics AG's Profit After Tax history spans 11 years, with the latest figure at -$130.6 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 250.07% year-over-year to -$130.6 million; the TTM value through Dec 2025 reached -$581.6 million, down 58.8%, while the annual FY2025 figure was -$581.6 million, 58.8% down from the prior year.
  • Profit After Tax for Q4 2025 was -$130.6 million at CRISPR Therapeutics AG, down from -$106.4 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $759.2 million in Q2 2021 and bottomed at -$208.5 million in Q2 2025.
  • The 5-year median for Profit After Tax is -$114.9 million (2021), against an average of -$68.7 million.
  • The largest annual shift saw Profit After Tax skyrocketed 1053.13% in 2021 before it plummeted 250.07% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$141.2 million in 2021, then rose by 21.72% to -$110.6 million in 2022, then soared by 180.8% to $89.3 million in 2023, then crashed by 141.76% to -$37.3 million in 2024, then tumbled by 250.07% to -$130.6 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Profit After Tax are -$130.6 million (Q4 2025), -$106.4 million (Q3 2025), and -$208.5 million (Q2 2025).